Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

详细信息    查看全文

• 作者：Sandip P. Patel (1)
  Takuya Osada (1)
  Koya Osada (1)
  Herbert Hurwitz (1)
  H. Kim Lyerly (1)
  Michael A. Morse (1)
  
• 关键词：Colorectal cancer ; Immune checkpoint ; CTLA ; 4 ; PD ; 1 ; PD ; L1 ; mCRC ; Immunomodulation ; Vaccine ; Colon cancer ; Ipilimumab ; Tremelimumab ; Nivolumab ; Lambrolizumab
• 刊名：Current Colorectal Cancer Reports
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：9
• 期：4
• 页码：391-397
• 全文大小：
• 作者单位：Sandip P. Patel (1)
  Takuya Osada (1)
  Koya Osada (1)
  Herbert Hurwitz (1)
  H. Kim Lyerly (1)
  Michael A. Morse (1)
  
  1. Department of Medicine, Division of Medical Oncology, Duke University Medical Center, DUMC 3841, Durham, NC, 27710, USA
  
• ISSN：1556-3804

文摘

T cell infiltration of colorectal cancer is associated with improved clinical outcome, underlining the importance of the immune system in cancer control; however, immune checkpoints, including the inhibitory T cell molecules CTLA-4 and PD-1 that temper the native immune response, mitigating autoimmunity, are coopted by tumors to facilitate escape from immune surveillance. Blockade of CTLA-4 and PD-1 and its ligand PD-L1, expressed by many tumors, have shown impressive activity in melanoma, renal cell carcinoma, and lung cancer. Immune checkpoint inhibition has been less well studied in colorectal cancer, but preclinical and clinical investigations are in progress.